Literature DB >> 3025130

Adenovirus type 3 infection with systemic manifestation in apparently normal children.

Y Levy, M Nitzan, A Beharab, A Zeharia, T Schoenfeld, J Nutman, L Rannon, R Steinherz.   

Abstract

Between July 1983 and February 1984, eight children with adenovirus Type 3 infection, proven by virus isolation from sputum, stool or nasopharyngeal swabs and a fourfold increase in complement fixation antibody titers against the virus, were treated in our department. All eight patients had fever lasting at least 7 days, hepatomegaly, diffuse pulmonary infiltrates and abnormal liver function tests. Seven of the patients exhibited dyspnea and pulmonary wheezing. Six of the patients developed changes in state of consciousness, and three had repeated convulsions. EEG patterns in three of the patients were compatible with encephalopathy. Other clinical manifestations included: follicular tonsillitis in two patients, diarrhea in two, pneumothorax in one, and shock with disseminated intravascular coagulation in one. The spectrum of adenovirus Type 3 infection reported here has been described previously only in the viral hemorrhagic fevers. This adenovirus Type 3 infection shares the potential for disseminated disease that has been described previously for Type 7, simulating Reye's syndrome.

Entities:  

Mesh:

Year:  1986        PMID: 3025130

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  2 in total

1.  Molecular epidemiology and restriction site mapping of adenovirus type 3 genome types.

Authors:  T Adrian; B Best; J C Hierholzer; R Wigand
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

2.  Type-specific clinical characteristics of adenovirus-associated influenza-like illness at five US military medical centers, 2009-2014.

Authors:  Michael A Koren; John C Arnold; Mary P Fairchok; Tahaniyat Lalani; Patrick J Danaher; Christina M Schofield; Michael Rajnik; Erin A Hansen; Deepika Mor; Wei-Ju Chen; Michelande Ridoré; Timothy H Burgess; Eugene V Millar
Journal:  Influenza Other Respir Viruses       Date:  2016-05-13       Impact factor: 4.380

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.